Neutropenia Clinical Presentation
- Author: John E Godwin, MD, MS; Chief Editor: Emmanuel C Besa, MD more...
History
Patients with neutropenia often present with infection. Other sequelae may reflect concurrent pancytopenia (which may increase the patient’s risk for spontaneous bleeding), with anemic symptoms (eg, fatigue, weakness, dyspnea on exertion) and symptoms of thrombocytopenia (eg, petechiae, purpura, epistaxis). For further information on pancytopenia, refer to Bone Marrow Failure.
Common presenting symptoms of neutropenia include the following:
- Low-grade fever
- Sore mouth
- Odynophagia
- Gingival pain and swelling
- Skin abscesses
- Recurrent sinusitis and otitis
- Symptoms of pneumonia (eg, cough, dyspnea)
- Perirectal pain and irritation
Patients with agranulocytosis usually present with the following:
- Sudden onset of malaise
- Sudden onset of fever, possibly with chills and prostration
- Stomatitis and periodontitis accompanied by pain
- Pharyngitis, with difficulty in swallowing
Determine if a fever is present, because the physician must be aware of a possible life-threatening infection. Obtaining a history of infections may aid in the current diagnostic workup. A history of periodically recurring infections is suggestive of cyclic neutropenia. A strong family history of recurrent infections, usually beginning in childhood, is strongly indicative of a genetic defect. Congenital neutropenia is suggested by a personal history of lifelong infections, family history of recurrent infections, documentation of longstanding neutropenia since childhood or adolescence, and absence of any other blood abnormality.
A family history of infections or sudden death may be an indication of inherited disorders. The maternal medical history (in neonatal neutropenia) may indicate inherited disorders or adverse effects of maternal medications. Records of past complete blood counts (CBCs) establish the chronicity of the neutropenia. Determining the age at onset aids in the differential diagnosis.
A patient with agranulocytosis may have experienced a recent viral infection, although such infections are rarely associated with severe neutropenia. Certain bacterial infections may also precede agranulocytosis.
Chronic, benign familial neutropenia is suggested by a history of long-standing neutropenia without an increased risk of infection. These patients do not generate increased leukocyte counts with infection, but they have fevers and other symptoms, such as tachycardia, when infected.
A history of autoimmune diseases may be associated with antineutrophil antibodies. Such antibodies may also be the only manifestation of autoimmune disease. A number of test methods are available, but none is widely used.
Primary immune neutropenia is uncommon. Secondary immune neutropenia may be associated with systemic lupus erythematosus, rheumatoid arthritis, and Felty syndrome.[2, 28, 29]
Obtaining a careful drug history may reveal the offending agent and spare the patient from an extensive diagnostic workup. Patients often report a history of a new drug being used or a recent change in medication. However, the offending medication may no longer be in use; therefore, the inquiry should extend back for some time. A history of occupational or accidental exposure to chemicals or physical agents (eg, ionizing radiation) may be noted.[30, 31]
If treatment is not promptly instituted, the infection progresses to generalized sepsis, which may become life threatening.
Go to Pediatric Autoimmune and Chronic Benign Neutropenia for complete information on this topic.
Physical Examination
Physical examination of a patient with neutropenia should focus on finding signs of an infection. The skin examination focuses on rashes, ulcers, or abscesses. The oral mucosa examination assesses for aphthous ulcers, thrush, or periodontal disease. Lymphadenopathy is a possible indication of a disseminated infection or, possibly, malignancy. For perirectal infections, look for abscesses or mucous membrane abnormalities. For perineal infections, look for rashes, abscesses, or lymphadenopathy. Lung infections are usually bacterial or fungal pneumonias.
Physical findings on examination of a patient with neutropenia may include the following:
- Fever
- Stomatitis
- Periodontal infection
- Cervical lymphadenopathy
- Skin infection
- Splenomegaly (see the image below)
- Associated petechial bleeding
- Perirectal infection
In agranulocytosis, fever (often 40°C or higher) may be present. Rapid pulse and respiration may be evident. Hypotension and signs of septic shock may be apparent if infection has been present. Painful aphthous ulcers may be found in the oral cavity. Swollen and tender gums may be present. Usually, purulent discharge is not present, because not enough neutrophils exist to form pus. Skin infections are associated with painful swelling, but erythema and suppuration are usually absent.
Watts RG. Neutropenia. In: Lee GR, Foerster J, Lukens J, et al, eds. Wintrobe's Clinical Hematology. 10th ed. Baltimore, Md: Lippincott, Williams & Wilkins; 1999:1862-1888.
Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams Hematology. 5th ed. New York, NY: McGraw-Hill; 1995:815-24, 844-58.
Lee GR, Foerster J, Lukens J, et al, eds. Wintrobe's Clinical Hematology. Vol 2. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:1862-82.
Curnutte J, Coates T. Disorder of phagocyte function and number. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. 3rd ed. New York, NY: Churchill Livingstone; 2000:720-62.
Haddy TB, Rana SR, Castro O. Benign ethnic neutropenia: what is a normal absolute neutrophil count?. J Lab Clin Med. Jan 1999;133(1):15-22. [Medline].
Mustafa MM, McClain KL. Diverse hematologic effects of parvovirus B19 infection. Pediatr Clin North Am. Jun 1996;43(3):809-21. [Medline].
Rodriguez A, Yood RA, Condon TJ, Foster CS. Recurrent uveitis in a patient with adult onset cyclic neutropenia associated with increased large granular lymphocytes. Br J Ophthalmol. May 1997;81(5):415. [Medline]. [Full Text].
Bar-Joseph G, Halberthal M, Sweed Y, Bialik V, Shoshani O, Etzioni A. Clostridium septicum infection in children with cyclic neutropenia. J Pediatr. Aug 1997;131(2):317-9. [Medline].
Lee GR, Foerster J, Lukens J, et al, eds. Wintrobe's Hematology. 10th ed. Baltimore, Md: William and Wilkins; 1999:1836-88.
Boxer LA. Immune neutropenias. Clinical and biological implications. Am J Pediatr Hematol Oncol. Spring 1981;3(1):89-96. [Medline].
Welte K, Dale D. Pathophysiology and treatment of severe chronic neutropenia. Ann Hematol. Apr 1996;72(4):158-65. [Medline].
Young NS. Agranulocytosis. JAMA. Mar 23-30 1994;271(12):935-8. [Medline].
Berliner N, Horwitz M, Loughran TP Jr. Congenital and acquired neutropenia. Hematology Am Soc Hematol Educ Program. 2004;63-79. [Medline].
Sifton DW, Murray L, Kelly GL, Reilly S, eds. Physicians' Desk Reference. 55th ed. Montvale, NJ: Medical Economics Company, Inc.; 2001:551-6, 847-60, 1275-80, 1396-9, 1793-5, 1998-2002, 3068-71.
American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. Nov 1994;12(11):2471-508. [Medline].
Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. Jun 1996;14(6):1957-60. [Medline].
Vial T, Gallant C, Choqu-Kastylevsky G, Descotes J. Treatment of drug-induced agranulocytosis with haematopoietic growth factors: a review of the clinical experience. BioDrugs. Mar 1999;11(3):185-200. [Medline].
D'Angelo G. Ethnic and genetic causes of neutropenia: clinical and therapeutic implications. Lab Hematol. 2009;15(3):25-9. [Medline].
[Best Evidence] Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev. Oct 8 2008;CD003189. [Medline].
D'Souza A, Jaiyesimi I, Trainor L, Venuturumili P. Granulocyte colony-stimulating factor administration: adverse events. Transfus Med Rev. Oct 2008;22(4):280-90. [Medline].
Kelly S, Wheatley D. Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. Br J Cancer. Sep 2009;101 Suppl 1:S6-10. [Medline]. [Full Text].
Carlsson G, Aprikyan AA, Ericson KG, Stein S, Makaryan V, Dale DC, et al. Neutrophil elastase and granulocyte colony-stimulating factor receptor mutation analyses and leukemia evolution in severe congenital neutropenia patients belonging to the original Kostmann family in northern Sweden. Haematologica. May 2006;91(5):589-95. [Medline].
Xia J, Bolyard AA, Rodger E, Stein S, Aprikyan AA, Dale DC, et al. Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia. Br J Haematol. Nov 2009;147(4):535-42. [Medline]. [Full Text].
Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med. Apr 3 2007;146(7):486-92. [Medline].
Grann VR, Bowman N, Joseph C, Wei Y, Horwitz MS, Jacobson JS, et al. Neutropenia in 6 ethnic groups from the Caribbean and the U.S. Cancer. Aug 15 2008;113(4):854-60. [Medline].
Cullen M, Baijal S. Prevention of febrile neutropenia: use of prophylactic antibiotics. Br J Cancer. Sep 2009;101 Suppl 1:S11-4. [Medline]. [Full Text].
Krell D, Jones AL. Impact of effective prevention and management of febrile neutropenia. Br J Cancer. Sep 2009;101 Suppl 1:S23-6. [Medline]. [Full Text].
Hellmich B, Schnabel A, Gross WL. Treatment of severe neutropenia due to Felty's syndrome or systemic lupus erythematosus with granulocyte colony-stimulating factor. Semin Arthritis Rheum. Oct 1999;29(2):82-99. [Medline].
Formiga F, Mitjavila F, Pac M, Moga I. Effective splenectomy in agranulocytosis associated with systemic lupus erythematosus. J Rheumatol. Jan 1997;24(1):234-5. [Medline].
MacVittie TJ. Therapy of radiation injury. Stem Cells. 1997;15 Suppl 2:263-8. [Medline].
Mac Manus M, Lamborn K, Khan W, Varghese A, Graef L, Knox S. Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model. Blood. Apr 1 1997;89(7):2303-10. [Medline].
Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis. Sep 1997;25(3):551-73. [Medline].
Bodey GP. Managing infections in the immunocompromised patient. Clin Infect Dis. Apr 1 2005;40 Suppl 4:S239. [Medline].
NCCN practice guidelines for fever and neutropenia. National Comprehensive Cancer Network. Oncology (Williston Park). May 1999;13(5A):197-257. [Medline].
Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med. May 30 1986;80(5C):13-20. [Medline].
Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. Jul 29 1999;341(5):312-8. [Medline].
Bow EJ, Mandell LA, Louie TJ, Feld R, Palmer M, Zee B, et al. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med. Aug 1 1996;125(3):183-90. [Medline].
Finberg RW, Talcott JA. Fever and neutropenia--how to use a new treatment strategy. N Engl J Med. Jul 29 1999;341(5):362-3. [Medline].
Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. Jul 29 1999;341(5):305-11. [Medline].
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Myeloid Growth Factors v 1. 2011. Available at http://www.nccn.org. Accessed April 21 2011.
[Best Evidence] Massey E, Paulus U, Doree C, Stanworth S. Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev. Jan 21 2009;CD005341. [Medline].
Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, et al. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model. Am J Clin Oncol. Aug 2008;31(4):369-74. [Medline].
Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. Mar 11 1999;340(10):764-71. [Medline].
| Syndrome | Inheritance | Gene | Clinical Features |
| Cyclic neutropenia | Autosomal dominant | ELA2 | Alternate 21-day cycling of neutrophils and monocytes |
| Kostmann syndrome | Autosomal recessive | Unknown | Stable neutropenia, no MDS or AML |
| Severe congenital neutropenia | Autosomal dominant | ELA2 (35-84%) | Stable neutropenia, MDS or AML |
| Autosomal dominant | GFI1 | Stable neutropenia, circulating myeloid progenitors, lymphopenia | |
| Sex linked | Wasp | Neutropenic variant of Wiskott-Aldrich syndrome | |
| Autosomal dominant | G-CSFR | G-CSF–refractory neutropenia, no AML or MDS | |
| Hermansky-Pudlak syndrome type 2 | Autosomal recessive | AP3B1 | Severe congenital neutropenia, platelet dense-body defect, oculocutaneous albinism |
| Chediak-Higashi syndrome | Autosomal recessive | LYST | Neutropenia, oculocutaneous albinism, giant lysosomes, impaired platelet function |
| Barth syndrome | Sex linked | TAZ | Neutropenia, often cyclic; cardiomyopathy, methylglutaconic aciduria |
| Cohen syndrome | Autosomal recessive | COH1 | Neutropenia, mental retardation, dysmorphism |
| Source: Modified from Berliner et al, 2004.[13] AML = acute myeloid leukemia; G-CSF = granulocyte colony-stimulating factor; MDS = myelodysplastic syndrome. | |||


